Hiteck(SZ:300683)2025-01-23 09:24Financial Projections - The estimated net profit for 2024 is projected to be a loss of between 57 million and 78 million RMB, compared to a loss of 120.82 million RMB in 2023[3] - The estimated operating revenue for 2024 is projected to be between 577.6 million and 704.49 million RMB, down from 602.28 million RMB in 2023[3] - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss of between 88 million and 120 million RMB, compared to a loss of 146.32 million RMB in 2023[3] Impairment and Losses - The company expects an impairment loss on inventory of approximately 8 million RMB due to lower sales prices and high fixed asset depreciation costs[6] - Non-recurring gains and losses are expected to impact net profit by approximately 31 million to 42 million RMB, primarily from investment income and government subsidies[6] Subsidiary and Business Challenges - The company has added a new consolidated subsidiary, Beijing Shadong Biotechnology Co., Ltd., which focuses on drug research and clinical trials, contributing to the overall net loss[5] - The company faces challenges in its raw materials and intermediates business due to intensified market competition and insufficient orders, leading to ongoing losses[5] Financial Data and Investor Advisory - The company has communicated with the accounting firm regarding the earnings forecast, and there are no discrepancies noted[4] - The financial data presented is preliminary and has not been audited by the accounting firm, with the final figures to be disclosed in the 2024 annual report[7] - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the financial data[7]